Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358570 | 0.93 | FGFR3 (0.80) | FGFR3KDR | |
| SCHEMBL15434059 | 0.92 | FGFR3 (0.69) | FGFR3KDR | |
| SCHEMBL3323358 | 0.91 | FGFR3 (0.85) | FGFR3KDR | |
| SCHEMBL3321802 | 0.88 | FGFR3 (0.81) | FGFR3KDR | |
| SCHEMBL11908174 | 0.88 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL11909312 | 0.88 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL13336792 | 0.88 | FGFR3 (0.88) | FGFR3KDR | |
| SCHEMBL13336859 | 0.88 | KDR (0.81) | FGFR3KDR | |
| SCHEMBL13062801 | 0.88 | FGFR3 (0.82) | FGFR3KDR | |
| SCHEMBL3322672 | 0.88 | FGFR3 (0.80) | FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109627239-B | Inhibitors of fibroblast growth factor receptors | 缆图药品公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180362613-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009047506-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047506-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885KDR 37/4885 |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885KDR 37/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885KDR 32/4885 |
| US-20180362613-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885KDR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.